This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Robotics Maker Ekso Aims to Help Wheelchair-Bound to Walk


Some of the money raised in the private placement will be used to augment the sales and marketing staff, according to the company. Currently the sales staff has seven members, five in the U.S. and two in Europe. Ekso has two people in marketing, one each in the U.S. and Europe, and three customer-relations employees. Additionally, the company has six clinical professionals and physical therapists. Each sale requires a clinician as well as an assist from customer service, according to Harding.

Ekso said in an SEC filing that its sales cycle ranges from three to 12 months. The company is working on shortening the cycle by increasing clinical awareness and acceptance of its product.

Ekso has 49 employees and plans to add 10 to 15 more over the next three months in its sales, clinical and manufacturing divisions.

As a public company, Ekso will have more access to a capital and will be better able to retain its engineering talent, Harding said. It may also give the company more credibility with prospective customers.

One customer who needs no convincing is Mena.

"I'm excited about the future, there are brilliant people working on this," she said. "The thing is, I was not hung up on walking, I didn't dream of walking, and when they talked to me about it, I wondered if I wanted to try it."

She is quiet for a moment, then she adds, "Why wouldn't I give myself the chance to walk again?"

5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
EKSO $1.03 0.00%
LMT $207.10 0.00%
AAPL $121.30 0.00%
FB $94.01 0.00%
GOOG $625.61 0.00%

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs